BeStock  
Stocks › Biotechnology › ADRX

Adarx Pharmaceuticals ADRX

US equityMarket cap rank #2910Biotechnology
$12.79 −$1.37 (-9.68%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.79 0.00%
Open$14.03
Prev close$14.16
Day range$12.63 – $14.87
Volume708.8K
Market cap$1.42B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

ADRX at a glance

Adarx Pharmaceuticals stock (ADRX) sits at $12.79, down 9.68% today. The business is worth $1.42B in the market, good for #2910 of 3753 on our coverage list.

It is close to the bottom of its 52-week range ($12.50 to $23.21), 44.9% under the high.

For the quarter ended Jun 2026 it reported $746,000.00 in revenue, up 258.7% from a year earlier, and a net loss of $25.76M.

4 analysts follow the stock and the average call is "buy". The mean target, $35.00, sits 173.7% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$12.70 / $18.90
Average price today$13.57
Volume708.8K
Turnover$9.62M
Turnover rate3.24%of shares outstanding
Volume ratio1.12vs. recent average pace
Day amplitude15.82%
Market cap$1.42B
Float market cap$279.78M
Shares outstanding21.88M
EPS (TTM)-$0.97
P/B2.48
Book value / share$5.17
Net profit (TTM)-$107.86M
Net assets$574.43M
30-day volatility78.8%annualized
Avg daily range (ATR)14.79%of price, 14 days
Max drawdown (1y)-38.0%-38.0% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

D
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

F
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

4 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$35.00+173.7% vs. current price
Consensus ratingBuy4 analysts covering
Morningstar fair value$15.28Price is below fair value

Wall Street’s average 12-month target is $35.00, 173.7% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $15.28, so shares trade 16.3% below that estimate. On earnings multiple, it sits in the 85th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-9.7%
1 week
-9.9%
1 month
-27.7%
Day range
$12.63$14.87
52-week range
$12.50$23.21

Technical signals

Full technicals →
Trend readStrong downtrend

0 bullish · 4 bearish of 4 signals

IndicatorValueSignal
Price vs 20-day average-14.6%Bearish
RSI (14)35.5Bearish
MACD (12,26,9)-1.20Bearish
Bollinger band position21%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How ADRX ranks on BeStock

Market value#2898 of 3734
Closeness to 52-week high#2851 of 3724
Dollar volume today#2418 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

ADRX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on ADRX.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on ADRX

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

ADRX stock: common questions

Where is ADRX trading right now?

$12.79 is the latest print for ADRX, a move of -9.68% against yesterday's close of $14.16. Today's low and high so far: $12.63 and $14.87.

How big is Adarx Pharmaceuticals?

Equity value comes to $1.42B at the current price. By that measure it is number 2910 of the 3753 names in our coverage.

Where does ADRX sit in its 52-week range?

The year's floor is $12.50 and the ceiling $23.21. Shares are 44.9% away from that ceiling.

Does ADRX send cash back through a dividend?

Our data shows no dividend paid by Adarx Pharmaceuticals over the trailing twelve months.

Do Wall Street analysts like ADRX?

Of 4 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $35.00, with the most cautious at $32.00 and the most optimistic at $38.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on ADRX.

Sign in to join the discussion.

Scroll to Top